Gilead Sciences

Foster City, California, USA

Gilead Sciences is a pharmaceutical company.

Shareable draft

Check out Gilead Sciences on @MedStartr Today Gilead Sciences is a pharmaceutical company. #HIVAIDS #HepatitisB #HepatitisC #Influenza #COVID19 #InflammatoryDiseases #FibroticDiseases #PrimaryBiliaryCholangitis #Lupus #RespiratoryConditions #CardiovascularConditions #MentalBehavioralHealth #InflammatoryBowelDisease #CancerOncology #DrugDiscoveryDevelopment #MedMo #MedStartrVentures

https://www.medstartr.ai/s/iGsBoaSm4O0

Note, this image was autogenerated by Syggy based on what we know about the company. It is not an official company publication.

Get Involved in Gilead Sciences

How We Help

Problem Statement

Gilead Sciences addresses unmet medical needs by discovering, developing, and commercializing innovative medicines, particularly for serious and life-threatening diseases.

Core Technology

Initially focused on antiviral therapeutics using nucleotide and nucleoside analogue chemistry. Current capabilities include antiviral chemistry expertise, cell and antibody-drug conjugate (ADC) capabilities, and leverages cloud, data, and AI/ML for drug discovery and development.

Key Differentiators

Innovative pipeline and breakthrough therapies (especially in antivirals for HIV and hepatitis C), R&D leadership, specialized expertise in antiviral chemistry and expanding oncology capabilities, patient-centric approach, strategic partnerships, global presence and access, commitment to health equity, and operational excellence.

Clinical Focus

Development of therapies for viral diseases (HIV/AIDS, hepatitis), various cancers, and inflammatory conditions, with a strong emphasis on antiviral chemistry, cell, and antibody-drug conjugate technologies.

Target Customers

Patients (indirectly), physicians, hospitals, and health systems globally.

Product Stage

Mature

Company Info

Business Model: Research-based, innovation-driven biopharmaceutical company. Discovers, develops, and commercializes innovative medicines, primarily through direct sales of proprietary drugs and therapies, licensing agreements, and collaboration partnerships. Employs a vertically integrated business model.
Founded: 1987
Total Funding: Only accessible to MedStartr community members. Join now
Only accessible to MedStartr community members.
Join now
Website: www.gilead.com

Disease Areas

HIV/AIDS Hepatitis B Hepatitis C Influenza COVID-19 Inflammatory Diseases Fibrotic Diseases Primary Biliary Cholangitis Lupus Respiratory conditions Cardiovascular Conditions Mental Health IBD Cancer & Oncology

Technologies

Antiviral ChemistryNucleotide Analogue ChemistryNucleoside Analogue ChemistryCell TherapyAI/ML for Drug DiscoveryAntibody-Drug Conjugates (ADCs)Data ScienceCloud Computing

Clinical & IP

🔬

Clinical Validation

OM336 (gamgertamig) has received FDA Fast Track and Orphan Drug Designation. Clinical trials demonstrated a single-tablet regimen of bictegravir and lenacapavir maintained virological suppression in people with HIV. The FDA approved a label update for Kite's Yescarta.

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of Gilead Sciences?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.